Table 1 Baseline characteristics of patients with CSA with and without US active inflammation: univariate analysis
Total n = 110 | US active inflammation n = 38 (34.5%) | Non-US active inflammation n = 72 (65.5%) | p | ||
|---|---|---|---|---|---|
Age | 53.6 ± 15.6 | 57.2 ± 16.2 | 51.6 ± 13.4 | 0.071 | |
Sex | Female | 80 (72.7%) | 26 (68.4%) | 54 (75%) | 0.461 |
Smoking, n = 87 | Non-smoker | 45 (51.7%) | 12 (44.4%) | 33 (55%) | 0.412 |
Smoker | 34 (39.1%) | 11 (40.7%) | 23 (38.3%) | ||
Former smoker | 8 (9.2%) | 4 (14.8%) | 4 (6.7%) | ||
Extension | Monoarticular | 12 (10.9%) | 6 (15.8%) | 6 (8.3%) | 0.176 |
Oligoarticular | 22 (20%) | 10 (26.3%) | 12 (16.7%) | ||
Polyarticular | 76 (69.1%) | 22 (57.9%) | 54 (75%) | ||
Time (months) from symptom onset | 11.7 ± 9.9 | 9.1 ± 8 .1 | 13 ± 10.5 | 0.035 | |
ESR (mm/h) | 24.7 ± 18.2 | 33.1 ± 21.8 | 20.3 ±14.4 | <0.001 | |
CRP (mg/dL) | 1.1 ± 3.1 | 1.4 ± 1.7 | 0.9 ± 3.7 | 0.329 | |
ANA | 15 (13.6%) | 5 (16.7%) | 10 (16.4%) | 0.748 | |
RF (IU/mL) | 39.1 ± 230.5 | 28.5 ± 56 | 45.1 ± 286.1 | 0.647 | |
ACPA (IU/mL) | 98.1 ± 331.2 | 209.4 ± 488.4 | 26 ± 125.2 | 0.01 | |